IN2012DN06436A - - Google Patents

Info

Publication number
IN2012DN06436A
IN2012DN06436A IN6436DEN2012A IN2012DN06436A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A IN 6436DEN2012 A IN6436DEN2012 A IN 6436DEN2012A IN 2012DN06436 A IN2012DN06436 A IN 2012DN06436A
Authority
IN
India
Prior art keywords
acceptable salt
pharmaceutically acceptable
piperazine
pharmaceutically
dioxoethyl
Prior art date
Application number
Inventor
Lin Pin-Fang
Nowicka-Sans Beata
Yamanaka Gregory
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06436(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IN2012DN06436A publication Critical patent/IN2012DN06436A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical composition comprising of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-lH- 1,2,4-triazol-l-yl)-lH-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, or a pharmaceutically acceptable salt thereof along with nucleoside HIV reverse transcriptase inhibitor selected from the group consisting of didanosine, emtricitabine and zalcitabine, including pharmaceutically acceptable salt thereof, used for treatment of AIDS or HIV infection, and a pharmaceutically, acceptable carrier, wherein the EC50 ratio of said piperazine compound to said other agent is 1:1, 1:2.5 or 2.5:1.
IN6436DEN2012 2004-03-24 2005-03-01 IN2012DN06436A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55576704P 2004-03-24 2004-03-24
PCT/US2005/006277 WO2005102392A2 (en) 2004-03-24 2005-03-01 Combinations for treating hiv infection

Publications (1)

Publication Number Publication Date
IN2012DN06436A true IN2012DN06436A (en) 2015-10-09

Family

ID=34961940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6436DEN2012 IN2012DN06436A (en) 2004-03-24 2005-03-01

Country Status (31)

Country Link
US (1) US7776863B2 (en)
EP (1) EP1732604B1 (en)
JP (1) JP4847441B2 (en)
KR (1) KR101158140B1 (en)
CN (1) CN1956720B (en)
AR (1) AR048333A1 (en)
AT (1) ATE474602T1 (en)
AU (1) AU2005235116B2 (en)
BR (1) BRPI0509140A (en)
CA (1) CA2561146C (en)
CY (1) CY1111613T1 (en)
DE (1) DE602005022420D1 (en)
DK (1) DK1732604T3 (en)
ES (1) ES2347801T3 (en)
GE (1) GEP20104925B (en)
HK (1) HK1096540A1 (en)
HR (1) HRP20100434T1 (en)
IL (1) IL178141A (en)
IN (1) IN2012DN06436A (en)
MY (1) MY144318A (en)
NO (1) NO337116B1 (en)
NZ (1) NZ549778A (en)
PE (1) PE20060148A1 (en)
PL (1) PL1732604T3 (en)
PT (1) PT1732604E (en)
RU (1) RU2367439C2 (en)
SI (1) SI1732604T1 (en)
TW (1) TWI347184B (en)
UA (1) UA88463C2 (en)
WO (1) WO2005102392A2 (en)
ZA (1) ZA200607959B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
JP5217438B2 (en) 2005-11-18 2013-06-19 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
JP5433691B2 (en) * 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Diketopiperidine derivatives as HIV binding inhibitors
JP5433690B2 (en) 2008-06-25 2014-03-05 ブリストル−マイヤーズ スクイブ カンパニー Diketo-fused azolopiperidine and azolopiperazine as anti-HIV drugs
US20110293521A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
WO2012019003A1 (en) 2010-08-06 2012-02-09 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
ES2585396T3 (en) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alkylamides as inhibitors of HIV binding
KR101848533B1 (en) 2011-01-31 2018-04-12 비브 헬스케어 유케이 (넘버4) 리미티드 Methods of making hiv attachment inhibitor prodrug compound and intermediates
WO2012142080A1 (en) 2011-04-12 2012-10-18 Bristol-Myers Squibb Company Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
ES2616432T3 (en) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivatives of tricyclic alkenes as inhibitors of HIV binding
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
JP6533514B2 (en) * 2013-03-27 2019-06-19 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 2-ketoamide derivatives as HIV binding inhibitors
EP3313412A4 (en) * 2015-06-23 2019-01-16 CytoDyn Inc. Inhibition of ccl5 ligand binding to ccr5 receptor and alteration of ccr5/ccl5 axis signaling in inflammation, cancer, autoimmune, and other conditions
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1068219T3 (en) * 1998-03-02 2007-04-30 Univ North Carolina Acylated betulin and dihydrobetulin derivatives as well as their preparation and use
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HUP0402675A2 (en) * 2001-12-12 2005-03-29 Bristol-Myers Squibb Co. Hydroxylamine-derivatives as hiv integrase inhibitors, pharmaceutical compositions containing them and use thereof
IL161784A0 (en) * 2001-12-21 2005-11-20 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Also Published As

Publication number Publication date
US7776863B2 (en) 2010-08-17
US20050215545A1 (en) 2005-09-29
ES2347801T3 (en) 2010-11-04
BRPI0509140A (en) 2007-09-04
SI1732604T1 (en) 2010-10-29
JP4847441B2 (en) 2011-12-28
CA2561146A1 (en) 2005-11-03
MY144318A (en) 2011-08-29
EP1732604B1 (en) 2010-07-21
GEP20104925B (en) 2010-03-25
HK1096540A1 (en) 2007-06-01
ATE474602T1 (en) 2010-08-15
ZA200607959B (en) 2008-06-25
TWI347184B (en) 2011-08-21
AR048333A1 (en) 2006-04-19
DE602005022420D1 (en) 2010-09-02
NZ549778A (en) 2010-09-30
EP1732604A2 (en) 2006-12-20
RU2367439C2 (en) 2009-09-20
CY1111613T1 (en) 2015-10-07
IL178141A0 (en) 2006-12-31
PE20060148A1 (en) 2006-03-04
NO20064547L (en) 2006-10-06
PT1732604E (en) 2010-09-24
RU2006137555A (en) 2008-04-27
UA88463C2 (en) 2009-10-26
DK1732604T3 (en) 2010-11-15
NO337116B1 (en) 2016-01-25
KR20070011322A (en) 2007-01-24
WO2005102392A2 (en) 2005-11-03
CA2561146C (en) 2013-12-24
AU2005235116B2 (en) 2011-03-31
IL178141A (en) 2010-11-30
JP2007530540A (en) 2007-11-01
CN1956720A (en) 2007-05-02
HRP20100434T1 (en) 2010-09-30
AU2005235116A1 (en) 2005-11-03
WO2005102392A3 (en) 2006-07-20
KR101158140B1 (en) 2012-06-19
CN1956720B (en) 2010-12-15
PL1732604T3 (en) 2010-12-31
TW200538117A (en) 2005-12-01

Similar Documents

Publication Publication Date Title
IN2012DN06436A (en)
WO2008054454A3 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
NZ627824A (en) Antiviral combinations involving (4r,12as)-n-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2hpyrido[1’,2’:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
TW200621762A (en) Novel compounds
MXPA04006553A (en) 4-oxoquinoline compound and its use as hiv integrase inhibitor.
EA200601654A1 (en) HIV INTEGRASE INHIBITORS
TW200510425A (en) Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
MX2007003321A (en) Heterocyclic derivatives and their use as therapeutic agents.
GB0112348D0 (en) Compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
SE0202463D0 (en) Novel compounds
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
GEP20125701B (en) Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
WO2008142055A3 (en) Antiviral agents
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
GB0106661D0 (en) Pharmaceutically active compounds
TW200745136A (en) 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CA2322900A1 (en) 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
MX2007004248A (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors.
NZ590128A (en) Prodrugs of HIV protease inhibitors
EP2033954A4 (en) 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
SG155939A1 (en) Phosphoindoles as hiv inhibitors